- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | BACK, ZPTA and ABVC are among premarket gainers | 4 | Seeking Alpha | ||
| 18.04. | ABVC BioPharma, Inc.: AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share | 130 | GlobeNewswire (Europe) | FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology... ► Artikel lesen | |
| 17.04. | ABVC BioPharma Enters Licensing Agreement With OncoX For Commercialization Of BLEX 404 | 1 | RTTNews | ||
| 17.04. | ABVC BioPharma executes licensing agreement with OncoX | 2 | Seeking Alpha | ||
| 17.04. | ABVC BioPharma, Inc.: ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M | 67 | GlobeNewswire (Europe) | FREMONT, CA, April 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in... ► Artikel lesen | |
| 17.04. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.04. | ABVC Biopharma stock climbs on deal for its oncology/hematology products | 1 | Seeking Alpha | ||
| 10.04. | ABVC BioPharma, Inc.: ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M | 1 | GlobeNewswire (USA) | ||
| 26.03. | Why ABVC BioPharma Stock Is Up Today | 1 | Benzinga.com | ||
| 26.03. | NeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare movers | 4 | Seeking Alpha | ||
| 26.03. | ABVC Announces Global Licensing Deal With ForSeeCon Eye For Vitargus | - | RTTNews | ||
| 26.03. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.03. | ABVC BioPharma, Inc.: ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M | 107 | GlobeNewswire (Europe) | FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology... ► Artikel lesen | |
| 22.03. | ABVC BIOPHARMA, INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 19.03. | ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine | 2 | GlobeNewswire (USA) | ||
| 14.03. | ABVC BioPharma GAAP EPS of -$2.43, revenue of $0.15M | 1 | Seeking Alpha | ||
| 14.03. | ABVC BioPharma, Inc.: ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update | 327 | GlobeNewswire (Europe) | FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a biotechnology company specializing in botanically based solutions that deliver... ► Artikel lesen | |
| 14.03. | ABVC BIOPHARMA, INC. - 8-K, Current Report | - | SEC Filings | ||
| 13.03. | ABVC BIOPHARMA, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 16.02. | ABVC BIOPHARMA, INC. - S-1/A, General form for registration of securities | 1 | SEC Filings |
Seite:
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,845 | -0,27 % | EQS-News: NanoRepro AG: Veröffentlichung von Kapitalmarktinformationen | EQS-News: NanoRepro AG
/ Schlagwort(e): Aktienrückkauf
NanoRepro AG: Veröffentlichung von Kapitalmarktinformationen
22.04.2024 / 12:00 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| BIOXXMED | 0,488 | +4,27 % | HV-Kalender: Aktionärs-Versammlungen u.a. bei bioXXmed, Shelly Group, Valneva | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,493 | +1,50 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,047 | +6,90 % | Sirona Biochem Corp.: SIRONA BIOCHEM Corporate Update April 2024 | VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona" or the "Company") provides the following update: Dear shareholders... ► Artikel lesen | |
| TREVENA | 0,391 | +4,83 % | TREVENA INC - 8-K, Current Report | ||
| REDHILL BIOPHARMA | 0,401 | -0,25 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| AFFIMED | 4,620 | -1,70 % | Affimed N.V.: Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology | The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,682 | +1,34 % | Phio Pharmaceuticals Corp.: Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells | -Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma... ► Artikel lesen | |
| IMMUNITYBIO | 6,800 | -0,96 % | Pre-market Movers: Abeona Therapeutics, HWH International, ImmunityBio, Hibbett, AGBA Group | NORWALK (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.55 A.M. ET).In the Green HWH International Inc. (HWH) is up over 42% at $1.83.
ImmunityBio... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 1,788 | -0,67 % | Emergent BioSolutions Inc. - 8-K, Current Report | ||
| BIOXCEL THERAPEUTICS | 2,384 | -2,30 % | BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting | Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University's Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE... ► Artikel lesen | |
| LEXICON PHARMACEUTICALS | 1,503 | +1,42 % | Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers | ||
| CELLECTIS | 2,340 | 0,00 % | Cellectis S.A. - 6-K, Report of foreign issuer | ||
| CHIMERIX | 0,842 | +0,36 % | Chimerix, Inc.: Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024 | ||
| CARA THERAPEUTICS | 0,678 | +6,19 % | Cara Therapeutics, Inc.: Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results | -Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)- -Completed enrollment of KOURAGE 1 Part A portion of NP pivotal... ► Artikel lesen |
ABVC BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,420 Euro und damit -10,69 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
